83% Decrease in Infant RSV Hospitalisation with Nirsevimab

In the Phase IIIb HARMONIE trial, nirsevimab (Beyfortus) drastically reduced infant respiratory syncitial virus (RSV) hospitalisations by 83%, and reduced all-cause lower respiratory tract infection hospitalisations by 58% (n = 8058).

RSV is the most common cause of respiratory tract infections in babies and young children. The data recently published in the New England Journal of Medicine was first shared in press releases by AstraZeneca and Sanofi in May 2023, which subsequently led to the nirsevimab FDA approval for the prevention of RSV in babies and toddlers in July 2023.